Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 5, 2015, Pages 353-360

  Sahota, Jaspreet Singh ^a   Smith, Claire Mary ^a,b   Radhakrishnan, Priya ^b   Winstanley, Craig ^c   Goderdzishvili, Marina ^d   Chanishvili, Nina ^d   Kadioglu, Aras ^c   O'Callaghan, Chris ^a,b   Clokie, Martha Rebecca Jane ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

Author keywords

bacteriophages; cystic fibrosis; nebulization; P. aeruginosa

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; HOST RANGE; HUMAN; LOWER RESPIRATORY TRACT; NEBULIZATION; NEBULIZER; NONHUMAN; PSEUDOMONAS AERUGINOSA; BIOLOGICAL THERAPY; MICROBIOLOGY; PHENOTYPE; PROCEDURES; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGE; VIROLOGY;

BIOLOGICAL THERAPY; CYSTIC FIBROSIS; HUMANS; NEBULIZERS AND VAPORIZERS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES;

EID: 84943267698     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1172     Document Type: Article

References (49)

1. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart C, and Walshaw MJ: Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet. 2001;358:558-560.
2. Hart CA, and Winstanley C: Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull. 2002;61:81-96.
3. Fothergill JL, Walshaw MJ, and Winstanley C: Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2012;40:227-238.
4. Cystic Fibrosis Trust: Cystic Fibrosis Trust. Cystic Fibrosis, frequently asked questions. Available at: www .cysticfibrosis.org.uk/about-cf/frequently-asked-questions. Accessed August 1, 2014.
5. Nordmann P, Naas T, Fortineau N, and Poirel L: Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. And Pseudomonas aeruginosa in 2010. Curr Opin Microbiol. 2007;10:436-440.
6. Kerr KG, and Snelling AM: Pseudomonas aeruginosa: A formidable and ever-present adversary. J Hosp Infect. 2009; 73:338-344.
7. Vogne C, Aires JR, Bailly C, Hocquet D, and Plesiat P: Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:1676-1680.
8. Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, Yagi T, Kato H, and Arakawa Y: Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet. 2003;362:1888-1893.
9. Martin K, Baddal B, Mustafa N, Perry C, Underwood A, Constantidou C, Loman N, Kenna DT, and Turton JF: Clusters of genetically similar isolates of Pseudomonas aeruginosa from multiple hospitals in the UK. J Med Microbiol. 2013;62:988-1000.
10. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, and Walshaw MJ: Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax. 2004;59:334-336.
11. Scott FW, and Pitt TL: Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol. 2004;53:609-615.
12. Ashish A, Shaw M, Winstanley C, Ledson MJ, and Walshaw MJ: Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)-A cause for concern? J Cyst Fibros. 2012;11:173-179.
13. Ryan EM, Gorman SP, Donnelly RF, and Gilmore BF: Recent advances in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63: 1253-1264.
14. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, and Yamaguchi K: Efficacy of bacteriophage therapy against gutderived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51:446-452.
15. Vinodkumar CS, Kalsurmath S, and Neelagund YF: Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol. 2008;51:360-366.
16. Wright A, Hawkins CH, Anggard EE, and Harper DR: A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; A preliminary report of efficacy. Clin Otolaryngol Surg. 2009;34:349-357.
17. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, and Sulakvelidze A: Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J Wound Care. 2009;18:237-238,240-243.
18. Hawkins C, Harper D, Burch D, Anggard E, and Soothill J: Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet Microbiol. 2010;146:309-313.
19. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, and Touqui L: Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201:1096-1104.
20. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA, and Winstanley C: Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med. 2011;183:1674-1679.
21. Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, and Surette MG: Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One. 2013; 8:e60225.
22. Winstanley C, Langille MG, Fothergill JL, Kukavica-Ibrulj I, Paradis-Bleau C, Sanschagrin F, Thomson NR, Winsor GL, Quail MA, Lennard N, Bignell A, Clarke L, Seeger K, Saunders D, Harris D, Parkhill J, Hancock RE, Brinkman FS, and Levesque RC: Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res. 2009;19:12-23.
23. Carter ME, Fothergill JL, Walshaw MJ, Rajakumar K, Kadioglu A, and Winstanley C: A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection. J Infect Dis. 2010;202:935-942.
24. Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet MM, Aaron SD, Charette SJ, Fothergill JL, Tucker NP, Winstanley C, and Levesque RC: Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients. PLoS One. 2014;9:e87611.
25. Freestone PP, Hirst RA, Sandrini SM, Sharaff F, Fry H, Hyman S, and O'Callaghan C: Pseudomonas aeruginosacatecholamine inotrope interactions: A contributory factor in the development of ventilator-associated pneumonia? Chest. 2012;142:1200-1210.
26. Kesarwani M, Hazan R, He J, Que YA, Apidianakis Y, Lesic B, Xiao G, Dekimpe V, Milot S, Deziel E, Lepine F, and Rahme LG: A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes. PLoS Pathog. 2011;7:e1002192.
27. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, and Abedon ST: Phage therapy in clinical practice: Treatment of human infections. Curr Pharm Biotechnol. 2010;11:69-86.
28. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, and Debarbieux L: Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS One. 2011;6: e16963.
29. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, and Johnson RP: Enumeration of bacteriophages by double agar overlay plaque assay. In: Clokie MRJ, Kropinski AM, eds. Bacteriophages: Methods and Protocols, Isolation: Characterization and Interactions. Vol 1. Humana Press; 2009:69-76.
30. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, and Vaneechoutte M: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4:e4944.
31. Alemayehu D, Casey PG, and McAuliffe O: Bacteriophages u MR299-2 and u NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012:3:e00029-12.
32. Mazzocco A. Waddell TE, Lingohr E, and Johnson R: Enumeration of bacteriophages using the small drop plaque assay system. In: Clokie MKA, ed. Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization and Interactions. Humana Press; 2009:81-85.
33. Evans TJ, Crow MA, Williamson NR, Orme W, Thomson NR, Komitopoulou E, and Salmond GP: Characterization of a broad-host-range flagellum-dependent phage that mediates high-efficiency generalized transduction in, and between, Serratia and Pantoea. Microbiology. 2010;156: 240-247.
34. Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, Thien H V, Vergnaud G, and Pourcel C: The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One. 2013; 8:e60575.
35. Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, and Winstanley C: Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol. 2010;59:472-481.
36. Salunkhe P, Smart CHM, Morgan JAW, Panagea S, Walshaw MJ, Hart CA, Geffers R, Tümmler B, and Winstanley C: A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol. 2005;187:4908-4920.
37. Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG, and Sulakvelidze A: A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002;41:453-458.
38. Kutateladze M, and Adamia R: Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591-595.
39. Torres-BarcelóC, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, and Hochberg ME: A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One. 2014;9:e106628.
40. Hall AR, De Vos D, Friman V-P, Pirnay J-P, and Buckling A: Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol. 2012;78:5646-5652.
41. Saye DJ, Ogunseitan O, Sayler GS, and Miller RV: Potential for transduction of plasmids in a natural freshwater environment: Effect of plasmid donor concentration and a natural microbial community on transduction in Pseudomonas aeruginosa. Appl Envir Microbiol. 1987;53:987-995.
42. Saye DJ, Ogunseitan OA, Sayler GS, and Miller RV: Transduction of linked chromosomal genes between Pseudomonas aeruginosa strains during incubation in situ in a freshwater habitat. Appl Environ Microbiol. 1990;56:140-145.
43. Geller DE: Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-670.
44. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, Finlay WH, Dennis JJ, and Vehring R: Respirable bacteriophages for the treatment of bacterial lung infections. J Aerosol Med Pulm Drug Deliv. 2013;26:317-335.
45. Golshahi L, Seed KD, Dennis JJ, and Finlay WH: Toward modern inhalational bacteriophage therapy: Nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv. 2008;21:351-360.
46. Golshahi L, Lynch KH, Dennis JJ, and Finlay WH: In vitro lung delivery of bacteriophages KS4-M and PhiKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol. 2011;110:106-117.
47. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, and Vehring R: Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011;100:5197-5205.
48. Semler DD, Goudie AD, Finlay WH, and Dennis JJ: Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother. 2014;58:4005-4013.
49. Manunta MD, McAnulty RJ, Tagalakis AD, Bottoms SE, Campbell F, Hailes HC, Tabor AB, Laurent GJ, O'Callaghan C, and Hart SL: Nebulization of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS One. 2011;6:e26768.